Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;103(12):5085-5101.
doi: 10.1007/s00277-024-06131-x. Epub 2024 Dec 9.

Advances in epigenetic therapies for B-cell non-hodgkin lymphoma

Weiwen Hu  1   2 , Lanlan Zang  3 , Xiaoxi Feng  1   2 , Shuhui Zhuang  1   2 , Liudi Chang  1   2 , Yongjing Liu  4 , Jinyan Huang  5 , Yuanyuan Zhang  6
Affiliations
Review

Advances in epigenetic therapies for B-cell non-hodgkin lymphoma

Weiwen Hu et al. Ann Hematol. 2024 Dec.

Abstract

B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30-40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.

Keywords: B-NHLs; Epigenetic drugs; Epigenetics; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: B-cell non-hodgkin lymphomas. Expert Rev Hematol 10(5):405–415. https://doi.org/10.1080/17474086.2017.1318053 - DOI - PubMed
    1. Chiu BC, Hou N (2015) Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res 165:1–25. https://doi.org/10.1007/978-3-319-13150-4_1 - DOI - PubMed
    1. Silkenstedt E, Salles G, Campo E, Dreyling M (2024) B-cell non-hodgkin lymphomas. Lancet 403(10438):1791–1807. https://doi.org/10.1016/S0140-6736(23)02705-8 - DOI - PubMed
    1. Solimando AG, Ribatti D, Vacca A, Einsele H (2016) Targeting B-cell non Hodgkin lymphoma: New and old tricks. Leuk Res 42:93–104. https://doi.org/10.1016/j.leukres.2015.11.001 - DOI - PubMed
    1. Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-Grade Lymphoma Study Group. Blood 106(12):3725–3732. https://doi.org/10.1182/blood-2005-01-0016 - DOI - PubMed

MeSH terms

LinkOut - more resources